Pharmaceuticals France

France mRNA Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

France mRNA Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Application, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $388.3 Mn Placeholder estimate
Estimate 2025 $408.9 Mn 2.4% of the global market
Projected 2034 $650.9 Mn 59.2% Adds $242.0 Mn over 9 forecast years
CAGR 2025–2034 5.3% Faster than 29% of 180 Pharmaceuticals markets here
Key players 6 +1
  • France is 2.43% of the global market.
  • In Europe, the largest is Germany at $514.6 Mn.
  • Fastest growing: Russia at 6.2% a year.
  • France ranks 4th of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$242.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
mRNA Therapeutics Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $388.3 Mn — —
2025 (base) $408.9 Mn +$20.6 Mn —
2026 (forecast) $430.6 Mn +$21.7 Mn +5.3%
2027 (forecast) $453.4 Mn +$22.8 Mn +10.9%
2028 (forecast) $477.5 Mn +$24.0 Mn +16.8%
2029 (forecast) $502.8 Mn +$25.3 Mn +22.9%
2030 (forecast) $529.4 Mn +$26.6 Mn +29.5%
2031 (forecast) $557.5 Mn +$28.1 Mn +36.3%
2032 (forecast) $587.0 Mn +$29.5 Mn +43.5%
2033 (forecast) $618.1 Mn +$31.1 Mn +51.2%
2034 (forecast) $650.9 Mn +$32.8 Mn +59.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

France mRNA Therapeutics Market Analysis at a glance
Market size, 2025$408.9 Mn placeholder estimate
Forecast, 2034$650.9 Mn placeholder estimate
Growth (CAGR), 2025–20345.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsApplication, type and end user (see all)
Key playersModerna, BioNTech, Pfizer Inc., CureVac, Arcturus Therapeutics and 1 more (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
Active clinical trials12 in FranceSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France mRNA Therapeutics Market Analysis Executive Summary

mRNA therapeutics use messenger RNA to make the body produce a protein, for vaccines, cancer treatments and rare diseases.

Key segments of the mRNA Therapeutics market include application (Infectious Disease Vaccines, Cancer Vaccines and Protein Replacement) and type (Prophylactic and Therapeutic).

Bar chart: France mRNA Therapeutics market size, 2024–2034, placeholder estimates. $388.3 Mn in 2024, $408.9 Mn in 2025 and $650.9 Mn in 2034, 5.3% CAGR.
France mRNA Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France mRNA Therapeutics Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the mRNA Therapeutics market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the mRNA Therapeutics market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the mRNA Therapeutics market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for mRNA Therapeutics Market in France

The mRNA Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for mRNA Therapeutics Market in France

mRNA Therapeutics in France: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2] ClinicalTrials.gov lists 12 studies on mRNA Therapeutics that are recruiting, active or about to start in France.⁠[3]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for mRNA Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in mRNA Therapeutics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

mRNA Therapeutics in context

France compared

  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[1]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the mRNA Therapeutics market in France?
Placeholder estimate: about $408.9 Mn in 2025, rising to about $650.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the mRNA Therapeutics market in France growing?
Placeholder estimate: about 5.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the mRNA Therapeutics market report cover?
The report splits the market by application (Infectious Disease Vaccines, Cancer Vaccines, Protein Replacement, Gene Editing Delivery), type (Prophylactic, Therapeutic) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the mRNA Therapeutics market?
Key players include Moderna, BioNTech, Pfizer Inc., CureVac, Arcturus Therapeutics and Sanofi.
What is driving the mRNA Therapeutics market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the mRNA Therapeutics market.
Who regulates mRNA Therapeutics in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
How many clinical trials on mRNA Therapeutics are running in France?
12 studies are recruiting, active or about to start in France, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
How much research is published on mRNA Therapeutics?
PubMed lists 652 papers on mRNA Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on vaccines and biologics and biosimilars

See the topic